The mammalian central nervous system is considered to be autonomous in lipid metabolism. Glial cells, in particular astrocytes, have been shown to be highly active in lipid synthesis and secretion. To determine the importance of astrocytes as lipid providers in the brain we generated mice in which the sterol regulatory elementbinding protein (SREBP) cleavage-activating protein (SCAP) was deleted from astrocytes using cre/lox technology. SCAP mutant mice showed microcephaly, without effects on astrocyte survival. SCAP deletion in astrocytes led to a loss of cholesterol and fatty acid synthesis pathways. SCAP mutants showed progressive motor deficits, dyskinesia and reduced anxiety. Interestingly, SCAP mutants showed changes in brain sterol and fatty acid profiles that were concordant with reduced lipid synthesis as well as with increased uptake of dietary lipids. Accordingly, a high-fat diet rich in cholesterol and mono-unsaturated fatty acids, but not a fish oil diet rich in polyunsaturated fatty acids, improved motor deficits and survival of the mutant mice.
Introduction
The brain is remarkably different in lipid composition than other organs. It is highly enriched in unsaturated fatty acids and cholesterol and it contains about one-quarter of the total amount of cholesterol in the body, whereas it comprises only 2% of total body weight (1) . The brain is very active in lipid synthesis as circulating lipids are largely excluded by the blood-brain barrier (1, 2) . This raises several important questions that remain to be answered. What are the specific functions of lipids in the brain, which cells are responsible for lipid synthesis in the brain, and what is the potential contribution of circulating lipids to the brain under disease conditions where in situ lipid synthesis is compromised?
Lipids function as building blocks for membranes, and are therefore important in myelination (3), neurite outgrowth (4), and synaptogenesis (5) . In addition, lipids act as signaling molecules in the brain (6) . Therefore, the brain's lipid metabolism requires a high level of regulation, and accordingly, several brain diseases were found caused by defective lipid metabolism. For instance, impaired cholesterol metabolism (e. g., Smith-Lemli-Opitz Syndrome, Nieman Pick Disease, Huntington's disease (HD) (1, (7) (8) (9) or fatty acid metabolism (e. g., Zellweger syndrome, adrenoleukodystrophy (10)) leads to severe neurodevelopmental impairments, including brain atrophy, mental retardation and motor dysfunction.
Several studies have suggested that glial cells, unlike neurons, are critical for the synthesis and metabolism of lipids in the brain (reviewed in (11) ). Unlike glia, neurons have a poor capacity to synthesize cholesterol (12) . Consistent with this, mice carrying a deletion of the squalene synthase (SQS) gene in adult cerebellar granular neurons do not have any morphological or functional defect (13) , showing that these neurons meet their cholesterol needs by uptake. In addition, astrocytes are active in desaturation and elongation of essential fatty acids (EFA) into polyunsaturated fatty acids (PUFAs) (14) , whereas neurons have been shown to take up astrocyte-derived PUFAs and to incorporate these into phospholipids (15) . Whereas oligodendrocytes synthesize lipids as constituents of myelin (3), astrocytes have been proposed to actively supply lipids to neurons and thereby regulate neurite outgrowth and synaptogenesis (4, 5, 12) .
Astrocyte lipids are derived from two sources. First, astrocytes may participate in uptake of lipids (e. g. EFAs and PUFA), from the blood-brain barrier by surrounding the capillary with their end feet (14, 16) . Second, astrocytes synthesize lipids themselves (4, 5, 12, 14, 17, 18) . By virtue of their close contacts with capillaries and neurons, they may supply neurons with lipids during development and mature functional activity (11) . However, in vivo evidence for the importance of astrocyte lipid metabolism to brain function is lacking.
We have recently demonstrated that lipid synthesis in Schwann cells, the myelinating glial cells of the peripheral nervous system (PNS), relies on sterol regulatory element binding proteins (SREBPs) (19) , basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factors that regulate lipid metabolism. SREBP transcription factors crucially rely on post-translational activation by the sterol sensor SCAP (20) .
In this report, we determined whether brain structure and function depends on astrocyte lipid synthesis after conditional ablation of SCAP in genetically engineered mice. We found that deletion of SCAP in astrocytes significantly reduced brain lipid levels leading to progressive motor deficits, behavioral dysfunction and premature death. Importantly, treatment with a diet enriched in the lipids depleted in the brains of these mice significantly improved survival and motor behavior. Our results demonstrate that reduced lipid synthesis in astrocytes causes severe neurological deficits that can be partially rescued by dietary lipid supplementation. This may have important implications for the understanding and treatment of neurological disorders that are associated with compromised brain lipid metabolism, such as Smith-LemliOpitz syndrome and Huntington's disease.
Materials and methods

Animals
SCAP-floxed mice were from the Jackson Laboratory (Bar Harbor, ME, USA) and have been described (20) . The hGFAP-Cre-IRES-LacZ transgenic mice have been described (21) Table 1 for diet components and fatty acid composition. These diets were given to the pregnant mice during the last week of gestation and during the lactation period until weaning (3 weeks after birth). At weaning, animals were separated, housed by gender, and continued to receive the same diet.
Behavioral assays
Behavioral tests were performed in 12 mutants and 12 wild-type animals within 4 weeks starting at 2.5 months of age. Unless indicated otherwise, mice were housed with their littermates of the same gender in Macrolon cages on sawdust bedding after weaning. Food and water were provided ad libitum. Housing was controlled for temperature, humidity and light-dark cycle (7 AM lights on, 7 PM lights off).
Animals were weighted weekly and the presence of abnormal movements, cage behavior and survival were scored. One week before the behavioral experiments, animals were housed individually in the same conditions as described above, with extra cardboard nesting material and a curved PVC tube. A metal food cup was placed in the home cage (for the purpose of habituation; used in subsequent hypophagia test).
All mice were subjected to all behavioral tests, and the order of the tests was identical for all mice. The same experimenter performed all tests. Tests are described below in the chronological order of use.
Open Field (OF). Locomotor activity was analyzed in the open field apparatus as described before (22) . Mice were transferred to the procedure room and allowed to Novelty induced hypophagia, was performed as described in (23) . During the first 3 test days, the familiar snack was introduced into the familiar metal food cup in the home cage and the latency to start eating was scored (maximum duration 240 s). If the subject did not start eating within 240 s, the maximum time was assigned. The mean latency to eat was calculated over 3 days. After 3 days, mice were transferred to a novel clean cage with fresh bedding containing the metal cup with the familiar snack.
The latency to start eating the snack was recorded manually. If a subject did not eat within 720 s, the maximum time was assigned.
Elevated plus maze (EPM). The EPM was performed as described in (22 Lipid analysis. Lipids were isolated from whole brain extracts (P14 and P120) by lipid extraction as described previously (19) . Neutral lipids were analyzed by HPLCtandem mass spectroscopy on a Sciex 4000 Q-TRAP mass spectrometer (AB Sciex,
Framingham, MA, USA), equipped with an atmospheric pressure chemical ionization (APCI) source. Free fatty acids, obtained by mild alkaline hydrolysis of isolated phospholipid fractions from lipid extracts, and intact phospholipids were analyzed as described previously (3, 19) by using defined molecular species and authentic free fatty acid standards for quantification purposes.
Immunoblotting: Whole-brain extracts (P14, P20 and P120) were mixed with SDS and heated to 90° C for 5 min. Proteins were separated by SDS-PAGE in a MiniProtean Electrophoresis system and electroblotted overnight onto PVDF membranes.
Membranes were probed with primary antibodies against ß-actin, SREBP1c (772 (24)) and SREBP2 (528 (25), both gift from H. Shimano) or a new generated antibody against the N-terminal part of mouse SREBP2 (amino acid 113-127) made by Genscript (Piscataway, NJ, USA), followed by an alkaline phosphatase-conjugated secondary antibody (Dako, 1:1000). After reaction with the ECF substrate (GE Healthcare) membranes were scanned with an FLA instrument (Fujifilm).
Quantification was done using the Quantity One software (Biorad).
Quantitative polymerase chain reaction
Primary cell cultures. Astrocyte cultures were derived from P0 wild-type and GFAP-SCAP mutant mice cortices. In brief, dissected cortices were treated with Trypsin (Life technologies, Inc., Carlsbad, CA, USA) followed by addition of trypsin inhibitor and gentle trituration, after which cells were resuspended in DMEM + Glutamax (Life Technologies, Inc.) containing 10% fetal bovine serum and cultured in non-coated plastic flasks. For harvesting, astrocytes, were briefly washed in PBS and taken up in TRIzol (Invitrogen). RNA extraction, cDNA synthesis and quantitative PCR experiments were performed as described below. Astrocyte purity of the culture was determined by immunostaining using GFAP as astrocyte specific markers, while counterstained for all cell nuclei with Hoechst, and determined to be higher than 95%.
Quantitative PCR Total mRNA from brain extracts (P0, P14 and P120) and cultured cells was isolated using TRIzol (Invitrogen), according the manufacturer's protocol.
cDNA synthesis and quantitative PCR reactions were done as described (19) . For total brain extracts results were normalized to the geometric mean of reference genes ß-actin, GAPDH, EF1a and Rsp1a. For astrocyte cultures results were normalized to GAPDH; EF1a and ß-actin were taken as potentially non-regulated controls. Table 2 shows the list of primers used. Sections were examined on a Zeiss microscope (Carl Zeiss GmbH, Jena, Germany), sampled with a Nikon video camera (Nikon, Tokyo, Japan) under fluorescent illumination, and cell density and region size were determined using Image J 1.42q software (U.S. National Institutes of Health, Bethesda, MD, USA). Six sets of matched sagittal sections were obtained and the 3 more medial slices of matched sets were compared per antibody. Using Image J, the cortex dorsal to the hippocampus was outlined and neurons within this area were counted. In hippocampus, neurons and astrocytes were counted and divided by the area. Finally, morphology of Bergmann glia was visualized with GFAP staining and photographed with a confocal microscope (Zeiss).
Immunohistochemistry
Results
SCAP deletion interferes with SREBP mediated gene expression in astrocytes
We generated mice carrying a deletion of the SCAP gene in astrocytes by crossing SCAP loxP mice (20) with mice expressing Cre recombinase under the control of the human GFAP promoter (21) . This GFAP-Cre transgenic mouse line has been described to predominantly target Cre-mediated recombination in the majority of astrocytes (21), and some granular neurons in the hippocampus (26) . In addition, some pyramidal cells in the cortex (26), a few basket and stellate neurons in the cerebellum (27) , and a small population of oligodendrocytes (28) may also be affected. This is notably very different from the extensively characterized hGFAP-Cre mouse that is used to target radial glia (29, 30) .
We found that astrocytes isolated from SCAP mutant mice had a strong reduction of SCAP mRNA levels to <20% of wild-type levels (Fig. 1A) . Furthermore, mRNA levels for SREBP1a, SREBP1c and SREBP2 were strongly reduced in SCAP mutant astrocytes (Fig. 1A) , which is in line with SCAP autoregulating, via the activation of SREBPs, the expression of the SREBP genes (19, 20) . EF1a and β-actin are not SCAP/SREBP targets and are shown as non-regulated controls. SCAP mutant mice showed a strong reduction of total brain mRNA levels for SCAP, SREBP1a, 1c and 2 at P0 and to a lesser extent at P14 (Fig. 1B) . The same was found for SCD1, a fatty acid desaturase under control of SREBP1c, and HMGCR, the rate-limiting enzyme in cholesterol synthesis and under control of SREBP2. Similarly, levels of SREBP1c and SREBP2 precursor proteins were reduced at P14 in mutant animals (Fig. 1C) . In adult SCAP mutants (P120), mRNA levels remained low for SREBP1c and SCD1, while SCAP, SREBP1a, SREBP2 and HMGCR, returned to control levels (Fig. 1B) . However, levels of SREBP1c and SREBP2 precursor proteins were reduced to nearly undetectable levels in both mutant and wild-type adult brains ( Fig   1C) . SCAP is required for processing of SREBPs into active transcription factors (20) , accordingly, reduced levels of cleaved (mature) SREBP2 proteins were detected at P20 in cortex and cerebellum of mutant animals ( Figure 1D ). A) mRNA levels for SCAP and SREBPs in primary cultured astrocytes (>95% GFAP positive) isolated from wild-type (wt) and GFAP-SCAP mutant (mt) animals were measured by quantitative PCR (n=3 independent cultures derived from separate animals). mRNA levels were first normalized to GAPDH, after which mt levels were normalized to wt levels in which the wt levels were set to 1. B) mRNA levels of SCAP, SREBPs and their target genes SCD1 and HMGCR were measured by quantitative PCR in total brain extracts at P0, P14 and P120 in wt (n= 3) and mt (n= 5, 5 and 3 respectively) animals. Transcript levels were first normalized to the geometric mean of reference genes ß-actin, GAPDH, EF1a and Rsp1a, after which mt levels were normalized to wt levels in which the wt levels were set to 1. C) Protein levels of precursor (unprocessed) SREBP1c (pSREBP1c) and pSREBP2 were determined by immunoblotting of total brain extracts of wt and mt animals at P14 and P120. β-actin was used to control for equal loading. Bars show quantification of protein levels at P14 that were first corrected for equal loading and subsequently normalized to wt levels in which the wt levels were set to 1. Protein quantification was not performed for P120 because SREBP1c and 2 protein levels were close to background. D) Protein levels of pSREBP2 and mature (processed) SREBP2 (mSREBP2), were determined by immunoblotting of total extracts of cortex and cerebellum of wt and mt animals at P20. Detection of mSREBP2 and pSREBP2 was done using different exposure times. β-actin was used to control for equal loading. Bars show quantification of pSREBP2 and mSREBP2 protein levels that were first corrected for equal loading and subsequently normalized to wt levels in which the wt levels were set to 1, and the ratio between mSREBP and pSREBP (ratio m/p) in which the ratio m/p for wt was set to 1. All data are presented as mean levels ± SEM (t-test: *= p < 0.05; **= p < 0.01).
The ratio between mature and unprocessed (precursor) pSREBP2 had decreased in mutant cerebellum, which was not observed in mutant cortex likely due to the (Fig. 2B) , whereas the total distance travelled remained the same, showing that mutant animals were affected in motor function although not in general activity. Cerebellum-dependent motor coordination was severely affected as determined with a Rotarod test (Fig. 2B ) in which the latency to fall from the accelerating rod was scored. Control animals showed improvement over 5 subsequent trials, whereas mutant animals did not. Mutant mice were significantly impaired in acoustic startle response (ASR). They responded to low pulse intensities as wild-type mice, however, with strongly reduced amplitudes (Fig. 2C) , demonstrating that the hearing function of the mutant was not affected but that motor output was impaired (Fig. 2C ). Prepulse inhibition (PPI), used as a measure of sensorimotor gating, was also impaired. It should be noted that acoustic stimuli still induced a startle response in mutant animals but did not induce PxD episodes (experimenter observations). Sensory nociceptive function of mutants was not affected as tested using a hot plate assay (Fig. 2C) . Anxiety behavior was determined first in the open field cage, in which the time spent in, and number of entries into the open field center area were not found to be different (Fig. 2D ), suggesting no difference in anxiety levels in this test. Next, anxiety behavior was determined in the elevated plus maze in which SCAP mutants were found to spend more time in the open arm than wild-types, whereas no difference in general activity was observed in terms of the number of entrances to the central compartment, suggestive of reduced anxiety levels (Fig. 2D) . Finally, in an assay for novel cage-induced hypophagia, mutant mice showed a shorter latency to eat in a novel cage than controls, whereas in the home cage no latency difference was observed suggesting no differences in motivation to consume the food (Fig. 2D) . Consistently with elevated plus maze behavior, this shows that SCAP mutants have reduced anxiety levels. In conclusion, SCAP deletion in astrocytes leads to progressive motor deficits, reduced anxiety, PxD episodes and premature death.
SCAP mutants have microcephaly but unaffected neuron-astrocyte ratios
Adult mutant brains (4 months) were reduced in size and weight (Fig. 3A) .
Microcephaly of mutant brains was detectable after the first postnatal week and increased progressively with age (Fig. 3A) . Whereas total cortical thickness was not affected, cortical layers II/III were smaller compared to controls (Fig. 3B) . The hippocampus showed a reduction in total area, although without obvious morphological changes in specific layers or regions (Fig. 3C ). Astrocytes were found in similar numbers in mutant and wild-type animals ( Table 3 ), indicating that astrocyte survival is not affected by SCAP mutation, like reported for liver cells (20) and Schwann cells (19) . Furthermore, similar numbers of neurons were found for mutant and wild-type animals (Table 3) . No obvious differences in cell size were found between mutants and wild-type mice for neurons and astrocytes using cell typespecific markers (Fig. 3D) . All layers of the cerebellum were reduced in size (Fig. 4A) . Whereas all principal lobules were present, there was defective foliation, and the intercrural fissure and intraculminate sulcus were not fully invaginated. In addition, a large number of NeuN-positive neurons were displaced in the cerebellar molecular layer (Fig. 4B) suggesting a migration and final positioning defect. GFAP staining of astrocytes revealed aberrant Bergmann glia morphology (Fig. 4C ). These results demonstrate that SCAP deletion in astrocytes leads to microcephaly, without an obvious reduction in cell size or specific loss of astrocytes or neurons, but with cerebellar migration defects associated with morphologically aberrant Bergman glia cells.
SCAP deletion in astrocytes leads to altered brain lipid composition and accumulation of dietary lipids
We next measured brain protein and lipid composition of early postnatal (P14) and adult (P120) animals. Protein concentration per brain did not differ between mutant and wild-type animals (Fig. 5A) . However, SCAP mutant brains contained less cholesterol at P120 (Fig. 5C) , and less desmosterol, an intermediate in cholesterol synthesis (Fig. 5D) . Interestingly, mutant brains (P120) contained more campesterol (Fig. 5E ), a plant sterol that is exclusively derived from dietary sources. These results demonstrate that SCAP mutant mouse brains have reduced synthesis of cholesterol, and increased accumulation of plasma-derived sterols. 
Table 3. Density of neurons and astrocytes in different brain region
Data based on staining depicted in Fig. 3 . Values are presented as mean ± SE percentage of wild-types (wt); n=3. mt, mutant; ND, not determined. (t-test: *= p < 0.05; **= p < 0.01).
The total amount of phospholipids per brain was not different in mutant animals at P14 (Fig. 5B) , however phospholipids contained less mono-unsaturated fatty acids (MUFA; Fig. 5F) . Accordingly, the level of oleic acid (18:1), one of the most prominent MUFA in the brain, was lower in mutants at P14 (Fig. 5F ). Mutant brains contained wild-type levels of docosahexaenoic acid (DHA) and arachidonic acid (AA) (Fig. 5, F-H) . However, levels of the essential fatty acids (EFA) linoleic (18:2) and linolenic (18:3) acid, that both function as precursors for AA and DHA synthesis respectively, were increased in mutant mice (Fig. 5F-H) . Because EFAs are only diet-derived, the accumulation of dietary EFAs in the brain is due to increased influx and/or compromised metabolism.
Legends on the next page
Thus, SCAP deletion in astrocytes reduces cholesterol and oleic acid synthesis in the brain, which is accompanied by an increased uptake of sterols and fatty acids from the circulation.
A high fat diet partially rescues motor control deficits and premature death of
SCAP mutant mice
Because mutant mice showed increased brain levels of dietary lipids, we tested whether we could rescue the phenotypes of SCAP mutant mice by further increasing dietary lipid intake. Mutant and wild-type mice were fed fat-enriched diets from embryonic day 15 onward and compared to mice fed a standard diet (SD). Fatenriched diets were either enriched in PUFAs (fish oil diet, FOD) or in cholesterol, MUFA and saturated fatty acids (high fat diet, HFD). Whereas a considerable number of animals on SD or FOD showed first episodes of paroxysmal dyskinesia at 6 weeks, none of the animals on HFD showed dyskinesia (Fig. 6A) . Furthermore, the majority of mutant mice on SD and FOD had severe attacks or had died with a history of PxD at 9 weeks, whereas only a small fraction of mutant animals on HFD had PxD episodes. It should be noted that after the age of 9 weeks, all mice fed HFD appeared unhealthy regardless of genotype. HFD had no effect on body weight within this time frame (Fig. 6B) . Apart from the effect of HFD on episodic attacks, at the age of 9 weeks, HFD also improved the motor function of mutant animals, since their maximum velocity in the open field was indistinguishable from controls while different from SD treated mutants (Fig. 6C) . Moreover, HFD significantly improved the ASR of mutant animals (Fig. 6D ) compared to SD treated mutants. HFD treated mutant and wild-type animals did no longer show a difference in PPI (Fig. 6E) . HFD did not improve microcephaly and reduced anxiety of mutant animals (Fig. 6F, G) . 
Discussion
Astrocyte SCAP deletion reduces cholesterol and oleic acid levels in the brain
We showed that SCAP is required for SREBP-mediated transcription in astrocytes with resulting alterations in both sterols and fatty acid composition of brains of SCAP mutant mice. Brain levels of oleic acid, the most prominent MUFA in the brain, were reduced in early postnatal SCAP mutants. Synthesis of oleic acid is dependent on the enzyme SCD1, which is transcriptionally regulated by SREBP1c (17) . Our observation that SCD1 levels are very low in SCAP mutant brains is consistent with previous findings that astrocytes are the major contributor of oleic acid in the brain (4, 17) . Interestingly, while SCD1 mRNA levels remain low in adult mutant brains, the level of oleic acid returns to normal, possibly through a slow uptake of oleic acid from the circulation (34) . Remarkably, astrocytes, unlike neurons are active in synthesis of PUFAs from EFAs (18) . However, our observation that levels of PUFAs, predominantly DHA and AA, are not altered in SCAP mutant brains indicates that those are not dependent on SREBP-mediated synthesis by astrocytes (11, 14, 18) , and instead, implies a major role for the uptake of PUFAs from the circulation (35).
We found brain cholesterol levels in mutants to be normal at early postnatal ages, and reduced in adults. Together, our data indicates that astrocyte lipid metabolism is critical for oleic acid accumulation, but not PUFAs, in the early postnatal brain, and is essential for the late postnatal growth or maintenance of cholesterol-rich membranes. SCAP mutant (mt) animals were fed a high fat diet (HFD; enriched in cholesterol and saturated/mono-unsaturated fatty acids), a fish oil diet (FOD; enriched in PUFA), or a standard diet (SD) from E15 onwards. A) mt and wt animals on SD, FOD or HFD were rated for neurological deficits at 6 and 9 weeks of age. B) Body weight of mice fed with the standard diet (SD) or high fat diet (HFD). In addition, the effect of HFD on velocity in Open Field (C), ASR (D), PPI (E) and elevated plus maze (F) was determined on mt and wt animals at 9 weeks of age. F) Cortical weight of wild-types (wt) and SCAP mutants (mt) of 9 weeks, fed with SD or HFD. Data are presented as means ± SEM. (ANOVA followed by Tukey's test: *= p < 0.05; **= p < 0.01; n= 10-12; p-values indicate differences between genotypes, not differences between diets).
Brain malformation by astrocyte SCAP deletion impacts most on the cerebellum
Substantial growth retardation was found in the cerebellum, with a general reduction in the thickness of multiple layers, and an aberrant accumulation of neurons in the molecular layer, both indicative of impaired migration of granular cells (36) .
Although only found for the cerebellum at P21, it cannot be excluded that neuronal migration was also compromised in other brain regions earlier in development. The GFAP-Cre line used in our study targets Bergman glia, but not cerebellar granule cells (27) For most types of PxD, the underlying molecular mechanism is not known (31, 32) . It should be noted that PxD in SCAP mice is progressive and accompanied by brain malformation and reduced survival, whereas symptoms in primary human PxD disappear in young adults and do not come with distinguishable malformations of the brain. The disorder in SCAP mutant mice therefore more likely resembles secondary PxD, as observed in humans with trauma or lesions of the CNS, vascular events or metabolic disorders (33) .
Interestingly, our observations on SCAP mutant mice may have implications for Huntington's disease (HD) (9) . HD patients and animal models thereof have reduced brain cholesterol levels, and expression of mutant huntingtin protein was shown to interfere with maturation of SREBP2 causing reduced SREBP mediated gene expression of lipogenic enzymes (38) . Furthermore, it was demonstrated that astrocytes in HD mice have impaired apoE-mediated cholesterol secretion (39) suggesting that interference of SREBP activation by mutant Huntingtin may interfere with lipid supply from astrocytes to neurons. Strikingly, like SCAP mutant mice, also rodent models for Huntington's disease show reduced ASR, reduced PPI and decreased anxiety (40, 41) . Taken together, our observations support a role of compromised astrocyte SREBP function in the pathophysiology underlying Huntington's disease.
Dietary lipids rescue SCAP mutant phenotypes
We found that a diet enriched in cholesterol and fatty acids (predominantly saturated and mono-unsaturated fatty acids) ameliorates neurological phenotypes of SCAP mutant mice, whereas a fish oil diet (enriched in PUFAs) had no such effect. These results are consistent with SCAP mutant mice having lower levels of MUFA and cholesterol, but not PUFAs. Importantly, high fat diet ameliorated the survival rate, PxD, maximal velocity, acoustic startle response and PPI, however, it did not rescue reduced anxiety, nor did it reduce weight of cerebellum or of total brain. Taken together, this suggests that motor dysfunctions and PxD share an underlying pathophysiological mechanism that may be different from the mechanisms leading to reduced anxiety. The lipid-dependent processes that underlie the neurological phenotypes in SCAP mutants may involve neurite outgrowth (4), synaptogenesis (5), plasticity of the tripartite synapse (6) or myelination (42) , for which a number of studies, mainly in vitro, have pointed to a role for astrocyte-derived lipids. On-going studies on the GFAP-SCAP mutant mouse are focused on defining the role of astrocyte-lipids in these processes.
We found that the levels of essential fatty acids, linoleic (18:2) and linolenic acid (18:3) that are able to cross the BBB (2), were elevated in SCAP mutant brains. In addition, we showed that SCAP mutant brains accumulate campesterol, a phytosterol exclusively synthesized by plants and therefore only obtained via the diet. The accumulation of phytosterols in the brain has also been shown for mice carrying a CNS specific deletion of the cholesterol transporter ABCA1, and is indicative for cholesterol transfer from plasma to brain (43) . Our observation that SCAP mutants have higher brain campesterol levels, while having lower cholesterol levels, strongly suggest an increased transfer of sterols from plasma to brain that may compensate for the loss of astrocyte-derived cholesterol, and suggest that the shielding of the CNS for circulating lipids may not be complete under conditions that brain lipid metabolism is compromised.
The molecular mechanism behind the elevated lipid influx in SCAP mutant brains remains unclear, but might involve the astrocytes capability to mediate lipid uptake from brain capillaries via interaction of endothelial cells with their endfeet (14, 16) .
Recently, various mechanisms were suggested to elevate lipid transport across the blood brain barrier (44, 45) , involving an increased angiogenesis of brain capillaries (46) , and/or increased expression of lipoprotein receptors in brain capillary cells (43) .
Interestingly, astrocytes were recently shown to promote BBB integrity via secretion of Sonic hedgehog (Shh) (47) , a molecule that needs covalent cholesterol modification for its biological activity. Whether Shh activity and BBB integrity is affected in astrocyte SCAP mutant mice is currently under investigation.
Implication for dietary treatment of neurological disorders associated with defective brain lipid metabolisms
Interestingly, in Smith-Lemli-Opitz syndrome (SLOS), patients present reduced cholesterol levels in all tissue, and cholesterol supplementation alleviates cognitive impairments and behavioral deficits in some patients (8) . In addition, amyotrophic lateral sclerosis (ALS) patients with elevated triglyceride and cholesterol serum levels have prolonged survival (48) , and a high fat diet has beneficial effects on an ALS mouse model (49) . Finally, addition of exogenous cholesterol to neurons expressing mutant huntingtin prevents their death in a dose dependent manner (38) , warranting lipid supplementation for treatment of Huntington's disease that has not been reported so far. Our data on SCAP mutant mice supports efforts in further engineering of dietary approaches to improve compromised CNS function as observed in Huntington's disease, SLOS, ALS, and possibly also Paroxysmal Dyskenisias.
In conclusion, our analysis demonstrates a crucial role for astrocyte SCAP in brain lipid metabolism necessary for proper brain development, function and behavior. Moreover, our study shows that neurological disorders associated to defective astrocyte lipid synthesis can be improved by lipid supplementation. This may have important implications for the understanding and treatment of neurological disorders that have been associated with compromised brain lipid metabolism, such as Smith-Lemli-Opitz syndrome and Huntington's disease.
